Neoadjuvant therapy for gastric cancer

Area of Science:

• Gastroenterology
• Surgical Oncology
• Medical Oncology

Background:

• Complete surgical resection is the primary curative treatment for early-stage gastric adenocarcinoma.
• A significant majority of patients (60%) undergoing resection present with advanced disease, facing a high risk of recurrence.
• Current treatment paradigms may not adequately address the high recurrence rates in patients with advanced gastric cancer post-resection.

Purpose of the Study:

• To advocate for rigorous preoperative staging to identify high-risk gastric cancer patients.
• To propose neoadjuvant chemotherapy for patients unlikely to benefit from surgery alone.
• To recommend adjuvant therapy for high-risk patients identified postoperatively.

Main Methods:

• Preoperative staging studies to assess disease risk.
• Administration of neoadjuvant chemotherapy prior to surgical resection for high-risk individuals.
• Postoperative assessment to guide adjuvant therapy selection.

Main Results:

• Identified that only 40% of patients have early-stage disease at the time of resection.
• Established that the majority of patients remain at high risk for recurrence after surgery alone.
• Highlighted the need for multimodal therapy in managing gastric adenocarcinoma.

Conclusions:

• Rigorous preoperative staging is crucial for tailoring gastric cancer treatment.
• Neoadjuvant chemotherapy followed by surgery offers a potential strategy for high-risk patients.
• Adjuvant therapy should be considered postoperatively to target likely sites of recurrence and improve survival outcomes.